nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—pancreatic cancer	0.424	1	CbGaD
Lenalidomide—ABCB1—Tamoxifen—pancreatic cancer	0.0298	0.199	CbGbCtD
Lenalidomide—ABCB1—Gemcitabine—pancreatic cancer	0.0257	0.172	CbGbCtD
Lenalidomide—ABCB1—Erlotinib—pancreatic cancer	0.0253	0.169	CbGbCtD
Lenalidomide—ABCB1—Irinotecan—pancreatic cancer	0.0229	0.153	CbGbCtD
Lenalidomide—ABCB1—Docetaxel—pancreatic cancer	0.0168	0.112	CbGbCtD
Lenalidomide—ABCB1—Sunitinib—pancreatic cancer	0.0167	0.112	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—pancreatic cancer	0.0125	0.0835	CbGbCtD
Lenalidomide—Pomalidomide—TNF—pancreatic cancer	0.00281	0.412	CrCbGaD
Lenalidomide—Thalidomide—TNF—pancreatic cancer	0.00181	0.266	CrCbGaD
Lenalidomide—Pomalidomide—PTGS2—pancreatic cancer	0.00134	0.196	CrCbGaD
Lenalidomide—Thalidomide—PTGS2—pancreatic cancer	0.000861	0.126	CrCbGaD
Lenalidomide—CDH5—Signaling Pathways—SSTR1—pancreatic cancer	0.000272	0.00344	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPY—pancreatic cancer	0.000266	0.00337	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—pancreatic cancer	0.000266	0.00337	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SSTR2—pancreatic cancer	0.000261	0.00331	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—pancreatic cancer	0.000259	0.00328	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCKBR—pancreatic cancer	0.000253	0.0032	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DTX4—pancreatic cancer	0.000237	0.00301	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GLI1—pancreatic cancer	0.000237	0.00301	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—DAXX—pancreatic cancer	0.000236	0.00298	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000231	0.00292	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRP1—pancreatic cancer	0.000231	0.00292	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TFF1—pancreatic cancer	0.00023	0.00291	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HEY2—pancreatic cancer	0.000222	0.00281	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—pancreatic cancer	0.000222	0.00281	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GAST—pancreatic cancer	0.000217	0.00275	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SCT—pancreatic cancer	0.000206	0.00261	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HEY1—pancreatic cancer	0.000206	0.00261	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	0.000197	0.00249	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCK—pancreatic cancer	0.000196	0.00249	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—pancreatic cancer	0.000193	0.00244	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR2—pancreatic cancer	0.000191	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GLP1R—pancreatic cancer	0.000191	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCKAR—pancreatic cancer	0.000188	0.00238	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000186	0.00235	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—GADD45A—pancreatic cancer	0.000186	0.00235	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JAG2—pancreatic cancer	0.000183	0.00231	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MEN1—pancreatic cancer	0.00018	0.00228	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HES1—pancreatic cancer	0.000179	0.00226	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—pancreatic cancer	0.000172	0.00217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SHH—pancreatic cancer	0.000172	0.00217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH4—pancreatic cancer	0.000171	0.00216	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IAPP—pancreatic cancer	0.00017	0.00215	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—DAXX—pancreatic cancer	0.000167	0.00211	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000166	0.0021	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTHLH—pancreatic cancer	0.000163	0.00206	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTCH1—pancreatic cancer	0.000163	0.00206	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—AGTR1—pancreatic cancer	0.000158	0.002	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SMAD4—pancreatic cancer	0.000157	0.00199	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	0.000149	0.00188	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SST—pancreatic cancer	0.000149	0.00188	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	0.000147	0.00186	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—pancreatic cancer	0.000147	0.00186	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JAG1—pancreatic cancer	0.000146	0.00184	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH3—pancreatic cancer	0.000145	0.00184	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000142	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—pancreatic cancer	0.000141	0.00178	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR1—pancreatic cancer	0.000137	0.00174	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—pancreatic cancer	0.000134	0.0017	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GCG—pancreatic cancer	0.000133	0.00168	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	0.000131	0.00166	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—pancreatic cancer	0.000129	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	0.000129	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	0.000128	0.00162	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AGTR1—pancreatic cancer	0.000127	0.0016	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	0.000126	0.0016	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	0.000126	0.0016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STK11—pancreatic cancer	0.000125	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—pancreatic cancer	0.00012	0.00152	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000118	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	0.000117	0.00149	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000115	0.00146	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	0.000115	0.00145	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	0.000109	0.00138	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMAD4—pancreatic cancer	0.000109	0.00138	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	0.000108	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000108	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000107	0.00135	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HES1—pancreatic cancer	0.000107	0.00135	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	0.000106	0.00134	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	0.000104	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—pancreatic cancer	0.000102	0.00129	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	9.79e-05	0.00124	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	9.48e-05	0.0012	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TERT—pancreatic cancer	9.35e-05	0.00118	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	9.31e-05	0.00118	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—RB1—pancreatic cancer	9.28e-05	0.00117	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	9.22e-05	0.00117	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	9.11e-05	0.00115	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—pancreatic cancer	9.04e-05	0.00114	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	8.96e-05	0.00113	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HIF1A—pancreatic cancer	8.94e-05	0.00113	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TSC2—pancreatic cancer	8.92e-05	0.00113	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—pancreatic cancer	8.72e-05	0.0011	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KDR—pancreatic cancer	8.55e-05	0.00108	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFKBIA—pancreatic cancer	8.13e-05	0.00103	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH1—pancreatic cancer	8.05e-05	0.00102	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	7.91e-05	0.001	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—pancreatic cancer	7.87e-05	0.000997	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—pancreatic cancer	7.79e-05	0.000985	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGF—pancreatic cancer	7.78e-05	0.000985	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	7.67e-05	0.000971	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—pancreatic cancer	7.39e-05	0.000936	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—pancreatic cancer	7.25e-05	0.000918	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—pancreatic cancer	7.23e-05	0.000915	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—pancreatic cancer	7.08e-05	0.000896	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	7.05e-05	0.000893	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	6.94e-05	0.000878	CbGpPWpGaD
Lenalidomide—Pruritus—Gemcitabine—pancreatic cancer	6.93e-05	0.000203	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CD—pancreatic cancer	6.92e-05	0.000876	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—pancreatic cancer	6.92e-05	0.000875	CbGpPWpGaD
Lenalidomide—Infection—Docetaxel—pancreatic cancer	6.9e-05	0.000202	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—pancreatic cancer	6.9e-05	0.000202	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—pancreatic cancer	6.89e-05	0.000202	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—pancreatic cancer	6.89e-05	0.000872	CbGpPWpGaD
Lenalidomide—Hyperglycaemia—Doxorubicin—pancreatic cancer	6.88e-05	0.000202	CcSEcCtD
Lenalidomide—Diarrhoea—Irinotecan—pancreatic cancer	6.88e-05	0.000202	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—pancreatic cancer	6.86e-05	0.000201	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—pancreatic cancer	6.84e-05	0.000201	CcSEcCtD
Lenalidomide—Shock—Docetaxel—pancreatic cancer	6.83e-05	0.000201	CcSEcCtD
Lenalidomide—Nervous system disorder—Docetaxel—pancreatic cancer	6.81e-05	0.0002	CcSEcCtD
Lenalidomide—Pruritus—Fluorouracil—pancreatic cancer	6.81e-05	0.0002	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—pancreatic cancer	6.8e-05	0.0002	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—pancreatic cancer	6.8e-05	0.000199	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—pancreatic cancer	6.8e-05	0.000199	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—pancreatic cancer	6.78e-05	0.000199	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	6.78e-05	0.000858	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	6.75e-05	0.000855	CbGpPWpGaD
Lenalidomide—Skin disorder—Docetaxel—pancreatic cancer	6.75e-05	0.000198	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	6.74e-05	0.000198	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	6.72e-05	0.00085	CbGpPWpGaD
Lenalidomide—Bradycardia—Epirubicin—pancreatic cancer	6.71e-05	0.000197	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—pancreatic cancer	6.7e-05	0.000848	CbGpPWpGaD
Lenalidomide—Diarrhoea—Gemcitabine—pancreatic cancer	6.7e-05	0.000197	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—pancreatic cancer	6.69e-05	0.000847	CbGpPWpGaD
Lenalidomide—Renal failure—Doxorubicin—pancreatic cancer	6.68e-05	0.000196	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.66e-05	0.000195	CcSEcCtD
Lenalidomide—Dizziness—Irinotecan—pancreatic cancer	6.65e-05	0.000195	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—pancreatic cancer	6.63e-05	0.000194	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—pancreatic cancer	6.63e-05	0.000194	CcSEcCtD
Lenalidomide—Anorexia—Docetaxel—pancreatic cancer	6.62e-05	0.000194	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—pancreatic cancer	6.61e-05	0.000194	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—pancreatic cancer	6.61e-05	0.000194	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—pancreatic cancer	6.61e-05	0.000194	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	6.6e-05	0.000835	CbGpPWpGaD
Lenalidomide—Hepatitis—Epirubicin—pancreatic cancer	6.6e-05	0.000193	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—pancreatic cancer	6.6e-05	0.000193	CcSEcCtD
Lenalidomide—Diarrhoea—Fluorouracil—pancreatic cancer	6.59e-05	0.000193	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—pancreatic cancer	6.56e-05	0.000193	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—pancreatic cancer	6.55e-05	0.000192	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—pancreatic cancer	6.52e-05	0.000191	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—pancreatic cancer	6.51e-05	0.000191	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—pancreatic cancer	6.51e-05	0.000824	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Epirubicin—pancreatic cancer	6.5e-05	0.000191	CcSEcCtD
Lenalidomide—Hypotension—Docetaxel—pancreatic cancer	6.49e-05	0.00019	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—pancreatic cancer	6.48e-05	0.00019	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—pancreatic cancer	6.48e-05	0.00019	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—pancreatic cancer	6.46e-05	0.00019	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—pancreatic cancer	6.43e-05	0.000189	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—pancreatic cancer	6.41e-05	0.000188	CcSEcCtD
Lenalidomide—Vomiting—Irinotecan—pancreatic cancer	6.39e-05	0.000187	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—pancreatic cancer	6.38e-05	0.000187	CcSEcCtD
Lenalidomide—Dizziness—Fluorouracil—pancreatic cancer	6.36e-05	0.000187	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—pancreatic cancer	6.36e-05	0.000186	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—pancreatic cancer	6.34e-05	0.000186	CcSEcCtD
Lenalidomide—Rash—Irinotecan—pancreatic cancer	6.34e-05	0.000186	CcSEcCtD
Lenalidomide—Dermatitis—Irinotecan—pancreatic cancer	6.33e-05	0.000186	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.33e-05	0.000186	CcSEcCtD
Lenalidomide—Headache—Irinotecan—pancreatic cancer	6.3e-05	0.000185	CcSEcCtD
Lenalidomide—Insomnia—Docetaxel—pancreatic cancer	6.28e-05	0.000184	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—pancreatic cancer	6.24e-05	0.000183	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—pancreatic cancer	6.24e-05	0.000183	CcSEcCtD
Lenalidomide—Vomiting—Gemcitabine—pancreatic cancer	6.22e-05	0.000183	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—pancreatic cancer	6.21e-05	0.000182	CcSEcCtD
Lenalidomide—Dyspnoea—Docetaxel—pancreatic cancer	6.19e-05	0.000182	CcSEcCtD
Lenalidomide—Somnolence—Docetaxel—pancreatic cancer	6.18e-05	0.000181	CcSEcCtD
Lenalidomide—Rash—Gemcitabine—pancreatic cancer	6.17e-05	0.000181	CcSEcCtD
Lenalidomide—Dermatitis—Gemcitabine—pancreatic cancer	6.17e-05	0.000181	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—pancreatic cancer	6.16e-05	0.000181	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—pancreatic cancer	6.15e-05	0.00018	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—pancreatic cancer	6.13e-05	0.00018	CcSEcCtD
Lenalidomide—Headache—Gemcitabine—pancreatic cancer	6.13e-05	0.00018	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—pancreatic cancer	6.12e-05	0.00018	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—pancreatic cancer	6.12e-05	0.00018	CcSEcCtD
Lenalidomide—Vomiting—Fluorouracil—pancreatic cancer	6.12e-05	0.00018	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—pancreatic cancer	6.12e-05	0.000179	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—pancreatic cancer	6.11e-05	0.000179	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—pancreatic cancer	6.1e-05	0.000179	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—pancreatic cancer	6.1e-05	0.000179	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.07e-05	0.000178	CcSEcCtD
Lenalidomide—Rash—Fluorouracil—pancreatic cancer	6.07e-05	0.000178	CcSEcCtD
Lenalidomide—Dermatitis—Fluorouracil—pancreatic cancer	6.06e-05	0.000178	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—pancreatic cancer	6.06e-05	0.000178	CcSEcCtD
Lenalidomide—Decreased appetite—Docetaxel—pancreatic cancer	6.04e-05	0.000177	CcSEcCtD
Lenalidomide—PTGS2—Disease—ZNRF3—pancreatic cancer	6.04e-05	0.000764	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRSS1—pancreatic cancer	6.04e-05	0.000764	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CB—pancreatic cancer	6.03e-05	0.000764	CbGpPWpGaD
Lenalidomide—Headache—Fluorouracil—pancreatic cancer	6.03e-05	0.000177	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.03e-05	0.000177	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—pancreatic cancer	6.01e-05	0.000176	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6e-05	0.000176	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—pancreatic cancer	6e-05	0.000176	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—pancreatic cancer	5.99e-05	0.000176	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—pancreatic cancer	5.98e-05	0.000176	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—pancreatic cancer	5.98e-05	0.000176	CcSEcCtD
Lenalidomide—Nausea—Irinotecan—pancreatic cancer	5.97e-05	0.000175	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—pancreatic cancer	5.96e-05	0.000175	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—pancreatic cancer	5.94e-05	0.000174	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—pancreatic cancer	5.94e-05	0.000174	CcSEcCtD
Lenalidomide—Pain—Docetaxel—pancreatic cancer	5.94e-05	0.000174	CcSEcCtD
Lenalidomide—Chills—Epirubicin—pancreatic cancer	5.92e-05	0.000174	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—pancreatic cancer	5.89e-05	0.000173	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—pancreatic cancer	5.88e-05	0.000173	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—pancreatic cancer	5.87e-05	0.000743	CbGpPWpGaD
Lenalidomide—Alopecia—Epirubicin—pancreatic cancer	5.83e-05	0.000171	CcSEcCtD
Lenalidomide—Nausea—Gemcitabine—pancreatic cancer	5.81e-05	0.000171	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—pancreatic cancer	5.8e-05	0.000734	CbGpPWpGaD
Lenalidomide—Mental disorder—Epirubicin—pancreatic cancer	5.78e-05	0.00017	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—pancreatic cancer	5.77e-05	0.000169	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—pancreatic cancer	5.74e-05	0.000168	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—pancreatic cancer	5.74e-05	0.000168	CcSEcCtD
Lenalidomide—Feeling abnormal—Docetaxel—pancreatic cancer	5.72e-05	0.000168	CcSEcCtD
Lenalidomide—Nausea—Fluorouracil—pancreatic cancer	5.72e-05	0.000168	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—pancreatic cancer	5.7e-05	0.000167	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—pancreatic cancer	5.7e-05	0.000721	CbGpPWpGaD
Lenalidomide—Tinnitus—Doxorubicin—pancreatic cancer	5.69e-05	0.000167	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.68e-05	0.000167	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—pancreatic cancer	5.66e-05	0.000166	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—pancreatic cancer	5.66e-05	0.000166	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—pancreatic cancer	5.66e-05	0.000166	CcSEcCtD
Lenalidomide—Tension—Epirubicin—pancreatic cancer	5.63e-05	0.000165	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—pancreatic cancer	5.62e-05	0.000165	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—pancreatic cancer	5.58e-05	0.000164	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—pancreatic cancer	5.55e-05	0.000163	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CASP3—pancreatic cancer	5.55e-05	0.000702	CbGpPWpGaD
Lenalidomide—Angiopathy—Doxorubicin—pancreatic cancer	5.54e-05	0.000162	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—pancreatic cancer	5.53e-05	0.000699	CbGpPWpGaD
Lenalidomide—Muscle spasms—Epirubicin—pancreatic cancer	5.52e-05	0.000162	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—pancreatic cancer	5.51e-05	0.000698	CbGpPWpGaD
Lenalidomide—Immune system disorder—Doxorubicin—pancreatic cancer	5.51e-05	0.000162	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.5e-05	0.000161	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—pancreatic cancer	5.49e-05	0.000161	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—pancreatic cancer	5.49e-05	0.000161	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—pancreatic cancer	5.48e-05	0.000161	CcSEcCtD
Lenalidomide—PTGS2—Disease—DTX1—pancreatic cancer	5.46e-05	0.000691	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—pancreatic cancer	5.45e-05	0.00016	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—pancreatic cancer	5.41e-05	0.000159	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—pancreatic cancer	5.4e-05	0.000684	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—pancreatic cancer	5.4e-05	0.000684	CbGpPWpGaD
Lenalidomide—Alopecia—Doxorubicin—pancreatic cancer	5.39e-05	0.000158	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—pancreatic cancer	5.39e-05	0.000682	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—pancreatic cancer	5.35e-05	0.000677	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—pancreatic cancer	5.35e-05	0.000157	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—pancreatic cancer	5.33e-05	0.000156	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—pancreatic cancer	5.31e-05	0.000156	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—pancreatic cancer	5.31e-05	0.000156	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—pancreatic cancer	5.31e-05	0.000156	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—pancreatic cancer	5.28e-05	0.000155	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—pancreatic cancer	5.24e-05	0.000664	CbGpPWpGaD
Lenalidomide—Flatulence—Doxorubicin—pancreatic cancer	5.23e-05	0.000154	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—pancreatic cancer	5.21e-05	0.00066	CbGpPWpGaD
Lenalidomide—Tension—Doxorubicin—pancreatic cancer	5.21e-05	0.000153	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—pancreatic cancer	5.2e-05	0.000153	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—pancreatic cancer	5.18e-05	0.000152	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—pancreatic cancer	5.16e-05	0.000151	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—pancreatic cancer	5.16e-05	0.000151	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—pancreatic cancer	5.15e-05	0.000151	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—pancreatic cancer	5.15e-05	0.000652	CbGpPWpGaD
Lenalidomide—Leukopenia—Epirubicin—pancreatic cancer	5.14e-05	0.000151	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—pancreatic cancer	5.14e-05	0.000151	CcSEcCtD
Lenalidomide—Hypersensitivity—Docetaxel—pancreatic cancer	5.12e-05	0.00015	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—pancreatic cancer	5.11e-05	0.00015	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—pancreatic cancer	5.07e-05	0.000149	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PRSS1—pancreatic cancer	5.05e-05	0.00064	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Epirubicin—pancreatic cancer	5.05e-05	0.000148	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—pancreatic cancer	5.03e-05	0.000637	CbGpPWpGaD
Lenalidomide—Cough—Epirubicin—pancreatic cancer	5.01e-05	0.000147	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—pancreatic cancer	5.01e-05	0.000147	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	5e-05	0.000633	CbGpPWpGaD
Lenalidomide—Asthenia—Docetaxel—pancreatic cancer	4.98e-05	0.000146	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—pancreatic cancer	4.96e-05	0.000145	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.93e-05	0.000145	CcSEcCtD
Lenalidomide—Pruritus—Docetaxel—pancreatic cancer	4.91e-05	0.000144	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—pancreatic cancer	4.91e-05	0.000144	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—pancreatic cancer	4.89e-05	0.000143	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—pancreatic cancer	4.89e-05	0.000143	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—pancreatic cancer	4.89e-05	0.000143	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—pancreatic cancer	4.88e-05	0.000143	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—pancreatic cancer	4.87e-05	0.000143	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.85e-05	0.000142	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SRC—pancreatic cancer	4.84e-05	0.000612	CbGpPWpGaD
Lenalidomide—Discomfort—Epirubicin—pancreatic cancer	4.83e-05	0.000142	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	4.81e-05	0.000609	CbGpPWpGaD
Lenalidomide—Malaise—Doxorubicin—pancreatic cancer	4.79e-05	0.000141	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	4.79e-05	0.000606	CbGpPWpGaD
Lenalidomide—Dry mouth—Epirubicin—pancreatic cancer	4.78e-05	0.00014	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—pancreatic cancer	4.77e-05	0.00014	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—pancreatic cancer	4.76e-05	0.00014	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—pancreatic cancer	4.76e-05	0.00014	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—pancreatic cancer	4.75e-05	0.000139	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—pancreatic cancer	4.72e-05	0.000139	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—pancreatic cancer	4.71e-05	0.000596	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—pancreatic cancer	4.69e-05	0.000138	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	4.69e-05	0.000593	CbGpPWpGaD
Lenalidomide—Oedema—Epirubicin—pancreatic cancer	4.69e-05	0.000137	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—pancreatic cancer	4.67e-05	0.000137	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—STAT3—pancreatic cancer	4.66e-05	0.00059	CbGpPWpGaD
Lenalidomide—Infection—Epirubicin—pancreatic cancer	4.65e-05	0.000137	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRAS—pancreatic cancer	4.65e-05	0.000589	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	4.64e-05	0.000587	CbGpPWpGaD
Lenalidomide—Cough—Doxorubicin—pancreatic cancer	4.64e-05	0.000136	CcSEcCtD
Lenalidomide—Shock—Epirubicin—pancreatic cancer	4.61e-05	0.000135	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—pancreatic cancer	4.6e-05	0.000135	CcSEcCtD
Lenalidomide—Dizziness—Docetaxel—pancreatic cancer	4.59e-05	0.000135	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—pancreatic cancer	4.59e-05	0.000135	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—pancreatic cancer	4.59e-05	0.000135	CcSEcCtD
Lenalidomide—PTGS2—Disease—DTX4—pancreatic cancer	4.57e-05	0.000579	CbGpPWpGaD
Lenalidomide—Tachycardia—Epirubicin—pancreatic cancer	4.57e-05	0.000134	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—pancreatic cancer	4.55e-05	0.000134	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—pancreatic cancer	4.54e-05	0.000574	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Epirubicin—pancreatic cancer	4.53e-05	0.000133	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	4.52e-05	0.000573	CbGpPWpGaD
Lenalidomide—Myalgia—Doxorubicin—pancreatic cancer	4.52e-05	0.000133	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—pancreatic cancer	4.52e-05	0.000133	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—pancreatic cancer	4.52e-05	0.000133	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—pancreatic cancer	4.51e-05	0.000132	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.49e-05	0.000132	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—pancreatic cancer	4.47e-05	0.000131	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—pancreatic cancer	4.47e-05	0.000131	CcSEcCtD
Lenalidomide—PTGS2—Disease—PPP2R5B—pancreatic cancer	4.45e-05	0.000563	CbGpPWpGaD
Lenalidomide—Dry mouth—Doxorubicin—pancreatic cancer	4.42e-05	0.00013	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—pancreatic cancer	4.42e-05	0.00013	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ARG2—pancreatic cancer	4.38e-05	0.000555	CbGpPWpGaD
Lenalidomide—Rash—Docetaxel—pancreatic cancer	4.38e-05	0.000129	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—pancreatic cancer	4.38e-05	0.000128	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—pancreatic cancer	4.38e-05	0.000128	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—pancreatic cancer	4.37e-05	0.000128	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.36e-05	0.000552	CbGpPWpGaD
Lenalidomide—Headache—Docetaxel—pancreatic cancer	4.35e-05	0.000128	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—pancreatic cancer	4.34e-05	0.000127	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—pancreatic cancer	4.33e-05	0.000548	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	4.32e-05	0.000547	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—pancreatic cancer	4.32e-05	0.000547	CbGpPWpGaD
Lenalidomide—Infection—Doxorubicin—pancreatic cancer	4.31e-05	0.000126	CcSEcCtD
Lenalidomide—PTGS2—Disease—HEY2—pancreatic cancer	4.28e-05	0.000542	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.27e-05	0.000125	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—pancreatic cancer	4.27e-05	0.000125	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—pancreatic cancer	4.25e-05	0.000125	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.24e-05	0.000125	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EGFR—pancreatic cancer	4.24e-05	0.000536	CbGpPWpGaD
Lenalidomide—Insomnia—Epirubicin—pancreatic cancer	4.24e-05	0.000124	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—pancreatic cancer	4.23e-05	0.000124	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—pancreatic cancer	4.21e-05	0.000124	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—pancreatic cancer	4.21e-05	0.000123	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	4.19e-05	0.000531	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.19e-05	0.000123	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—pancreatic cancer	4.18e-05	0.000123	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—pancreatic cancer	4.17e-05	0.000122	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—pancreatic cancer	4.13e-05	0.000121	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—pancreatic cancer	4.13e-05	0.000121	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—pancreatic cancer	4.12e-05	0.000121	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	4.09e-05	0.000517	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—pancreatic cancer	4.07e-05	0.00012	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—pancreatic cancer	4.05e-05	0.000119	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.05e-05	0.000119	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—pancreatic cancer	4.04e-05	0.000119	CcSEcCtD
Lenalidomide—Pain—Epirubicin—pancreatic cancer	4.01e-05	0.000118	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—pancreatic cancer	4.01e-05	0.000118	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KRAS—pancreatic cancer	4e-05	0.000507	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HEY1—pancreatic cancer	3.97e-05	0.000502	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.95e-05	0.000116	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—pancreatic cancer	3.92e-05	0.000115	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—pancreatic cancer	3.89e-05	0.000114	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—pancreatic cancer	3.87e-05	0.000113	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—pancreatic cancer	3.86e-05	0.000113	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—pancreatic cancer	3.85e-05	0.000113	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.83e-05	0.000112	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—TYMP—pancreatic cancer	3.83e-05	0.000485	CbGpPWpGaD
Lenalidomide—Dyspepsia—Doxorubicin—pancreatic cancer	3.82e-05	0.000112	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—pancreatic cancer	3.77e-05	0.000111	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	3.76e-05	0.000476	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	3.75e-05	0.000475	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.74e-05	0.00011	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—pancreatic cancer	3.74e-05	0.00011	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—pancreatic cancer	3.72e-05	0.000109	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—pancreatic cancer	3.71e-05	0.000109	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—pancreatic cancer	3.71e-05	0.000109	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—pancreatic cancer	3.7e-05	0.000109	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—pancreatic cancer	3.7e-05	0.000109	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—pancreatic cancer	3.68e-05	0.000466	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	3.68e-05	0.000465	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	3.68e-05	0.000465	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRSS1—pancreatic cancer	3.58e-05	0.000454	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—pancreatic cancer	3.57e-05	0.000105	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—pancreatic cancer	3.56e-05	0.00045	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.55e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Disease—JAG2—pancreatic cancer	3.52e-05	0.000445	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	3.5e-05	0.000443	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	3.47e-05	0.00044	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MEN1—pancreatic cancer	3.47e-05	0.000439	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—pancreatic cancer	3.45e-05	0.000101	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—pancreatic cancer	3.44e-05	0.000101	CcSEcCtD
Lenalidomide—PTGS2—Disease—SLC2A2—pancreatic cancer	3.44e-05	0.000436	CbGpPWpGaD
Lenalidomide—Body temperature increased—Doxorubicin—pancreatic cancer	3.43e-05	0.000101	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—pancreatic cancer	3.43e-05	0.000101	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	3.41e-05	0.000432	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—pancreatic cancer	3.4e-05	0.000431	CbGpPWpGaD
Lenalidomide—Asthenia—Epirubicin—pancreatic cancer	3.36e-05	9.86e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	3.32e-05	0.00042	CbGpPWpGaD
Lenalidomide—Pruritus—Epirubicin—pancreatic cancer	3.32e-05	9.73e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—SHH—pancreatic cancer	3.31e-05	0.000419	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	3.29e-05	0.000416	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IAPP—pancreatic cancer	3.27e-05	0.000413	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	3.21e-05	0.000406	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—pancreatic cancer	3.21e-05	9.41e-05	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—pancreatic cancer	3.19e-05	9.37e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	3.19e-05	0.000404	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.16e-05	0.0004	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSPA1B—pancreatic cancer	3.13e-05	0.000397	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—pancreatic cancer	3.11e-05	9.13e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ARG2—pancreatic cancer	3.11e-05	0.000393	CbGpPWpGaD
Lenalidomide—Dizziness—Epirubicin—pancreatic cancer	3.1e-05	9.09e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GLP1R—pancreatic cancer	3.09e-05	0.000391	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	3.09e-05	0.000391	CbGpPWpGaD
Lenalidomide—Pruritus—Doxorubicin—pancreatic cancer	3.07e-05	9e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—DPYD—pancreatic cancer	3.04e-05	0.000384	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—pancreatic cancer	3e-05	0.00038	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—pancreatic cancer	2.98e-05	8.74e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	2.97e-05	0.000376	CbGpPWpGaD
Lenalidomide—Diarrhoea—Doxorubicin—pancreatic cancer	2.97e-05	8.7e-05	CcSEcCtD
Lenalidomide—Rash—Epirubicin—pancreatic cancer	2.95e-05	8.67e-05	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—pancreatic cancer	2.95e-05	8.66e-05	CcSEcCtD
Lenalidomide—Headache—Epirubicin—pancreatic cancer	2.94e-05	8.61e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	2.9e-05	0.000367	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A2—pancreatic cancer	2.88e-05	0.000365	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—pancreatic cancer	2.87e-05	8.41e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.85e-05	0.000361	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAG1—pancreatic cancer	2.81e-05	0.000355	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—pancreatic cancer	2.78e-05	8.17e-05	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—pancreatic cancer	2.76e-05	8.09e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.75e-05	0.000348	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—pancreatic cancer	2.73e-05	8.02e-05	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—pancreatic cancer	2.73e-05	8.01e-05	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—pancreatic cancer	2.72e-05	7.97e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—TYMP—pancreatic cancer	2.72e-05	0.000344	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD44—pancreatic cancer	2.67e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	2.66e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	2.66e-05	0.000336	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSPA1A—pancreatic cancer	2.65e-05	0.000335	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.61e-05	0.00033	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	2.61e-05	0.00033	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—pancreatic cancer	2.58e-05	7.56e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.51e-05	0.000317	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	2.48e-05	0.000314	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	2.46e-05	0.000312	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	2.26e-05	0.000286	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CD44—pancreatic cancer	2.23e-05	0.000283	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GLP1R—pancreatic cancer	2.19e-05	0.000277	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	2.19e-05	0.000277	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.19e-05	0.000277	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DPYD—pancreatic cancer	2.15e-05	0.000273	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCG—pancreatic cancer	2.14e-05	0.000271	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SMAD4—pancreatic cancer	2.1e-05	0.000266	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—pancreatic cancer	2.05e-05	0.00026	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A2—pancreatic cancer	2.04e-05	0.000259	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STK11—pancreatic cancer	2.01e-05	0.000255	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.89e-05	0.000239	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.85e-05	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—pancreatic cancer	1.8e-05	0.000228	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—pancreatic cancer	1.73e-05	0.000219	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—pancreatic cancer	1.72e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TSC2—pancreatic cancer	1.72e-05	0.000217	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—pancreatic cancer	1.68e-05	0.000213	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CD44—pancreatic cancer	1.58e-05	0.0002	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—pancreatic cancer	1.55e-05	0.000196	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCG—pancreatic cancer	1.52e-05	0.000192	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGF—pancreatic cancer	1.5e-05	0.00019	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STK11—pancreatic cancer	1.43e-05	0.000181	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—pancreatic cancer	1.41e-05	0.000178	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—pancreatic cancer	1.33e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.33e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—pancreatic cancer	1.27e-05	0.000161	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—pancreatic cancer	1.23e-05	0.000155	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—pancreatic cancer	1.23e-05	0.000155	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—pancreatic cancer	1.16e-05	0.000147	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—pancreatic cancer	1.12e-05	0.000141	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—pancreatic cancer	1.03e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—pancreatic cancer	1e-05	0.000127	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—pancreatic cancer	9.98e-06	0.000126	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—pancreatic cancer	9.73e-06	0.000123	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—pancreatic cancer	9.31e-06	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—pancreatic cancer	9.01e-06	0.000114	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—pancreatic cancer	8.98e-06	0.000114	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—pancreatic cancer	8.96e-06	0.000113	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—pancreatic cancer	8.69e-06	0.00011	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—pancreatic cancer	8.41e-06	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—pancreatic cancer	8.35e-06	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—pancreatic cancer	8.33e-06	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—pancreatic cancer	8.16e-06	0.000103	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—pancreatic cancer	7.92e-06	0.0001	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—pancreatic cancer	7.71e-06	9.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—pancreatic cancer	7.09e-06	8.97e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—pancreatic cancer	6.9e-06	8.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—pancreatic cancer	6.84e-06	8.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—pancreatic cancer	6.56e-06	8.3e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—pancreatic cancer	5.96e-06	7.55e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—pancreatic cancer	5.93e-06	7.51e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—pancreatic cancer	5.79e-06	7.33e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—pancreatic cancer	4.85e-06	6.14e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—pancreatic cancer	4.21e-06	5.32e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—pancreatic cancer	3.44e-06	4.35e-05	CbGpPWpGaD
